|
4.12 BIOPSIES LIQUIDES
|
|
|
|
|
5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE
|
|
|
|
5.2 PHARMA
|
|
|
|
5.2.6 PHARMA - BIOTECH
|
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
|
|
|
|
|
|
5.3.4.1 TRAITEMENTS - AMM (FDA, EMA,...) - SELPERCATINIB
|
|
|
|
|
|
|
|
Eli Lilly Gets Edge in the “RET” Race With FDA Nod for Cancer Drug [Xconomy]
|
|
|
|
|
|
Selpercatinib, a capsule taken twice daily, is designed to block an enzyme that aids this tumor growth. But before a patient receives the Lilly drug, the RET gene alteration must be confirmed by a lab test. As of now, there is no FDA-approved companion diagnostic for detecting RET fusions or mutations.
|
|
|
|
|
|
|
5.3.4.2 TRAITEMENTS - AMM (FDA, EMA,...) - OLAPARIB
|
|
|
|
5.4 TRAITEMENTS - ECONOMIE
|
|
|
|
|
5.5.1.1 ASCO (GÉNÉRAL) - INDUSTRIELS
|
|
|
|
|
|
6.15 LUTTE CONTRE LES CANCERS - COVID-19
|
|
|
|
|